{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:52:31Z","timestamp":1792785151132,"version":"4.5.0"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"07","funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background\u2003A strong association between on-thienopyridine platelet reactivity (PR) and the risk of both thrombotic and bleeding events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) has been demonstrated. However, no study has analyzed the relationship between on-ticagrelor PR and clinical outcome in this clinical setting.<\/jats:p>\n                  <jats:p>Objectives\u2003We aimed to investigate the relationship between on-ticagrelor PR, assessed by the vasodilator-stimulated phosphoprotein (VASP) index, and clinical outcome in patients with ACS undergoing PCI.<\/jats:p>\n                  <jats:p>Methods\u2003We performed a prospective, multicenter, observational study of patients undergoing PCI for ACS. PR was measured using the VASP index following ticagrelor loading dose. The primary study endpoint was the rate of Bleeding Academic Research Consortium (BARC) type \u22652 at 1 year. The key secondary endpoint was the rate of major adverse cardiovascular events (MACE) defined as the composite of cardiovascular death, myocardial infarction, stroke, and urgent revascularization.<\/jats:p>\n                  <jats:p>Results\u2003We included 570 ACS patients, among whom 33.9% had ST-elevation myocardial infarction. BARC type \u22652 bleeding occurred in 10.9% and MACE in 13.8%. PR was not associated with BARC \u22652 or with MACE (p\u2009=\u20090.12 and p\u2009=\u20090.56, respectively). No relationship between PR and outcomes was observed, neither when PR was analyzed quantitatively nor when it was analyzed qualitatively (low on-treatment PR [LTPR] vs. no LTPR).<\/jats:p>\n                  <jats:p>Conclusion\u2003On-ticagrelor PR measured by the VASP was not associated with bleeding or thrombotic events in ACS patients undergoing PCI. PR measured by the VASP should not be used as a surrogate endpoint in studies on ticagrelor.<\/jats:p>","DOI":"10.1055\/a-1326-5110","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T19:54:01Z","timestamp":1606852441000},"page":"923-930","source":"Crossref","is-referenced-by-count":8,"title":["On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome"],"prefix":"10.1055","volume":"121","clinical-trial-number":[{"clinical-trial-number":"nct02428725","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1458-5543","authenticated-orcid":false,"given":"Marc","family":"Laine","sequence":"additional","affiliation":[{"name":"Intensive care Unit, Department of Cardiology, Assistance publique des hopitaux de Marseille, H\u00f4pital Nord, Aix Marseille University, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0012-1289","authenticated-orcid":false,"given":"Vassili","family":"Panagides","sequence":"additional","affiliation":[{"name":"Intensive care Unit, Department of Cardiology, Assistance publique des hopitaux de Marseille, H\u00f4pital Nord, Aix Marseille University, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-4732","authenticated-orcid":false,"given":"Corinne","family":"Fr\u00e8re","sequence":"additional","affiliation":[{"name":"Institute of Cardiometabolism And Nutrition, INSERM UMRS_1166, GRC 27 GRECO, Sorbonne Universit\u00e9, Paris, France"},{"name":"Department of Haematology, Assistance Publique-H\u00f4pitaux de Paris, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cuisset","sequence":"additional","affiliation":[{"name":"Department of Cardiology, CHU Timone, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gouarne","sequence":"additional","affiliation":[{"name":"Intensive care Unit, Department of Cardiology, Assistance publique des hopitaux de Marseille, H\u00f4pital Nord, Aix Marseille University, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France"},{"name":"Department of Haematology, Assistance Publique-H\u00f4pitaux de Paris, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Jouve","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital of Aix-en-Provence, F-13100 Aix-en-Provence, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Lemesle","sequence":"additional","affiliation":[{"name":"USIC et Centre H\u00e9modynamique, Institut C\u0153ur Poumon, Centre Hospitalier Universitaire de Lille, Lille, France"},{"name":"Facult\u00e9 de M\u00e9decine de l'Universit\u00e9 de Lille, Lille, France"},{"name":"INSERM UMR 1011, Institut Pasteur de Lille, Lille, France"},{"name":"FACT (French Alliance for Cardiovascular Trials), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Paganelli","sequence":"additional","affiliation":[{"name":"Intensive care Unit, Department of Cardiology, Assistance publique des hopitaux de Marseille, H\u00f4pital Nord, Aix Marseille University, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Alessi","sequence":"additional","affiliation":[{"name":"Centre for CardioVascular and Nutrition Research (C2VN), INSERM 1263, INRA 1260, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mancini","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille, INSERM, IRD, SESSTIM, CHU Timone, Department of Public Health (BIOSTIC), Aix Marseille Universit\u00e9, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bonello","sequence":"additional","affiliation":[{"name":"Intensive care Unit, Department of Cardiology, Assistance publique des hopitaux de Marseille, H\u00f4pital Nord, Aix Marseille University, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,1,26]]},"reference":[{"issue":"07","key":"ref1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"S Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"M Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"17","key":"ref3","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"A Sch\u00f6mig","year":"1996","journal-title":"N Engl J Med"},{"issue":"24","key":"ref4","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"U S Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"ref5","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"P A Gurbel","year":"2003","journal-title":"Circulation"},{"issue":"14","key":"ref6","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","article-title":"Antiplatelet agents for the treatment and prevention of coronary atherothrombosis","volume":"70","author":"C Patrono","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"ref7","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"P A Gurbel","year":"2009","journal-title":"Circulation"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","article-title":"Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome","volume":"63","author":"L Bonello","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/jth.12360","article-title":"Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism","volume":"11","author":"S Nylander","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/CIRCULATIONAHA.113.002589","article-title":"Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial","volume":"128","author":"P G Steg","year":"2013","journal-title":"Circulation"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention","volume":"35","author":"D Aradi","year":"2014","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"D Sibbing","year":"2017","journal-title":"Lancet"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1538-7836.2009.03709.x","article-title":"Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement","volume":"8","author":"D Sibbing","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref15","first-page":"551","article-title":"Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events","volume":"112","author":"D Alexopoulos","year":"2014","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1160\/TH13-05-0384","article-title":"Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study","volume":"111","author":"M Laine","year":"2014","journal-title":"Thromb Haemost"},{"issue":"14","key":"ref17","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"139","author":"F Franchi","year":"2019","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2017.07.013","article-title":"Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI","volume":"192","author":"P Dehghani","year":"2017","journal-title":"Am Heart J"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/jth.12907","article-title":"High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis","volume":"13","author":"G Lemesle","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1111\/jth.14592","article-title":"Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome","volume":"17","author":"M Laine","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.5603\/KP.2015.0243","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation [in Polish]","volume":"73","author":"M Roffi","year":"2015","journal-title":"Kardiol Pol"},{"issue":"04","key":"ref22","first-page":"702","article-title":"Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome","volume":"114","author":"L Bonello","year":"2015","journal-title":"Thromb Haemost"},{"issue":"17","key":"ref23","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"D E Cutlip","year":"2007","journal-title":"Circulation"},{"issue":"09","key":"ref24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"A S Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"27","key":"ref25","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"D Aradi","year":"2015","journal-title":"Eur Heart J"},{"issue":"14","key":"ref26","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study","volume":"51","author":"L Bonello","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"ref27","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study","volume":"59","author":"D Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","article-title":"Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial","volume":"124","author":"M J Price","year":"2011","journal-title":"Circulation"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1373\/clinchem.2004.047050","article-title":"Monitoring of clopidogrel action: comparison of methods","volume":"51","author":"J Geiger","year":"2005","journal-title":"Clin Chem"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/ATVBAHA.118.310224","article-title":"Platelet signaling pathways and new inhibitors","volume":"38","author":"S P Grover","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1326-5110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T10:17:57Z","timestamp":1660126677000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1326-5110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":30,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2021,6,27]]},"published-print":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1326-5110","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]}}}